2 research outputs found
Effects of angiotensin-converting enzyme inhibition with perindopril on left ventricular remodeling and clinical outcome - Results of the randomized Perindopril and Remodeling in Elderly with Acute Myocardial Infarction (PREAMI) study
Background: Angiotensin-converting enzyme inhibitors
reduce mortality and remodeling after myocardial
infarction in patients with left ventricular dysfunction.
Methods: Perindopril and Remodeling in Elderly With
Acute Myocardial Infarction (PREAMI), a doubleblind,
randomized, parallel-group, multicenter, placebocontrolled
study, determined whether similar benefits occur
in elderly postinfarction patients with preserved left
ventricular function. A total of 1252 patients 65 years or
older with a left ventricular ejection fraction of 40% or
higher and recent acute myocardial infarction were randomized
to receive perindopril erbumine or placebo (8
mg/d) for 12 months. The combined primary end point
was death, hospitalization for heart failure, or left ventricular
remodeling. Secondary end points included cardiovascular
death, hospitalization for reinfarction or angina,
and revascularization.
Results: The primary end point occurred in 181 patients
(35%) taking perindopril and 290 patients (57%)
taking placebo, with a significant absolute risk reduction
of 0.22 (95% confidence interval, 0.16 to 0.28;
P.001). A total of 126 patients (28%) and 226 patients
(51%) in the perindopril and placebo groups, respectively,
experienced remodeling. The mean increase in left
ventricle end-diastolic volume was 0.7 mL with perindopril
compared with 4.0 mL with placebo (P.001). In
the perindopril group, 40 deaths (6%) and 22 hospitalizations
(4%) for heart failure occurred, whereas 37 deaths
(6%) and 30 hospitalizations (5%) occurred in the placebo
group. Treatment did not affect death, whereas the
hospitalization rate for heart failure was slightly reduced
(absolute risk reduction, 0.01; 95% confidence interval,
−0.01 to 0.02). No treatment effect on other secondary
end points was detected.
Conclusion:Wefound that 1-year treatment with 8mg/d
of perindopril reduces progressive left ventricular remodeling
that can occur even in the presence of small
infarct size, but it was not associated with better clinical
outcomes
Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease:: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study)
Background Treatment with angiotensin-converting-enzyme (ACE) inhibitors reduces the rate of cardiovascular events among patients with left-ventricular dysfunction and those at high risk of such events. We assessed whether the ACE inhibitor perindopril reduced cardiovascular risk in a low-risk population with stable coronary heart disease and no apparent heart failure.Methods We recruited patients from October, 1997, to June, 2000. 13 655 patients were registered with previous myocardial infarction (64%), angiographic evidence of coronary artery disease (61%), coronary revascularisation (55%), or a positive stress test only (5%). After a run-in period of 4 weeks, in which all patients received perindopril, 12 218 patients were randomly assigned perindopril 8 mg once daily (n=6110), or matching placebo (n=6108). The mean follow-up was 4.2 years, and the primary endpoint was cardiovascular death, myocardial infarction, or cardiac arrest. Analysis was by intention to treat.Findings Mean age of patients was 60 years (SD 9), 85% were male, 92% were taking platelet inhibitors, 62% beta blockers, and 58% lipid-lowering therapy. 603 (10%) placebo and 488 (8%) perindopril patients experienced the primary endpoint, which yields a 20% relative risk reduction (95% CI 9-29, p=0.0003) with perindopril. These benefits were consistent in all predefined subgroups and secondary endpoints. Perindopril was well tolerated.Interpretation Among patients with stable coronary heart disease without apparent heart failure, perindopril can significantly improve outcome. About 50 patients need to be treated for a period of 4 years to prevent one major cardiovascular event. Treatment with perindopril, on top of other preventive medications, should be considered in all patients with coronary heart disease